Preclinical evidence supports targeting GPER as a strategy to overcome tamoxifen resistance: GPER knockdown or co-treatment with the GPER antagonist G15 attenuates breast cancer cell proliferation (70), and combining G15 with tamoxifen restores sensitivity in tamoxifen-resistant MCF-7 xenografts. This evidence concerns the gene GPER1 and breast cancer.